Lansinoh names new VP marketing
ALEXANDRIA, Va. A maker of breast-feeding products has named Michael Barclay, a former SC Johnson brand manager, as its new VP marketing.
In his new role at Lansinoh, Barclay will coordinate all North American marketing activities while leading the brand marketing, consumer relations and professional relations teams. He will report to Lansinoh North America president Diane Manwaring. Prior to joining Lansinoh, Barclay was the brand manager for SC Johnson’s wax division and category manager for Frito-Lay’s U.K. division.
“Lansinoh has made great strides in the last several years and continues to work toward aggressive goals for growth in 2011 and beyond,” said Kevin Vyse-Peacock, CEO of Lansinoh. “Michael brings to the team extensive experience in product management and consumer packaged goods. He has the strategic thinking skills needed to direct the development of creative, effective, socially integrated marketing campaigns. We’re excited to have him on board.”
Trojan picks up good vibrations
PRINCETON, N.J. Condom producer Trojan is launching a new line of vibrators, the company said Tuesday.
Trojan announced the introduction of Trojan Vibrations, which it described as powerful but with soft textures. The first, Vibrating Tri-Phoria, will become available in retail pharmacies and mass merchandisers in 2011.
“We’ve built a better vibrator for women and men to enjoy,” Trojan VP marketing Jim Daniels said. “We did our homework, and we listened to our consumers. We know that women and men want trusted and reliable pleasure products, and our world-class [research and development] team responded with a pioneering line of vibrators that will keep up the pleasure quotient during sex, and add some adventure and fun to America’s bedrooms.”
Decision Resources: Generic competition will crush hypertension drug market
BURLINGTON, Mass. The market for hypertension drugs will drop by $3 billion by the end of the decade due to generic competition, according to a new report by healthcare market research firm Decision Resources.
The report, announced Tuesday, found that the market for drugs to treat high blood pressure would decline from 2009’s $26 billion to $23 billion by 2019 in the United States, United Kingdom, France, Italy, Spain and Japan.
The largest decline will hit Novartis’ Diovan (valsartan), which will lose more than $1 billion in sales in 2013, following market entry of generic versions of the drug.
“Emerging agents will find it difficult to penetrate the highly genericized hypertension market because of competition from inexpensive and efficacious generic anti-hypertensive drugs,” Decision Resources analyst Taskin Ahmed said. “Through 2019, we do not forecast blockbuster sales for any of the emerging anti-hypertensive agents.”